Skip to main content

Role of Pathologist in Precision Cancer Diagnosis

  • 172 Accesses

Abstract

Immunohistochemistry (IHC) currently represents the most widely used approach for cancer biomarker analysis in routine pathology practice. It is applied as a descriptive, qualitative, tissue-based, in situ protein immunoassay, for which the readout of the results is principally performed by pathologists using a light microscope or whole slide digital image system.

This is a preview of subscription content, access via your institution.

Buying options

Chapter
USD   29.95
Price excludes VAT (USA)
  • DOI: 10.1007/978-3-030-84087-7_16
  • Chapter length: 13 pages
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
eBook
USD   129.00
Price excludes VAT (USA)
  • ISBN: 978-3-030-84087-7
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
Hardcover Book
USD   169.99
Price excludes VAT (USA)

References

  • Allison KH, Hammond MEH, Dowsett M, McKernin SE, Carey LA, Fitzgibbons PL, Hayes DF, Lakhani SR, Chavez-MacGregor M, Perlmutter J, Perou CM, Regan MM, Rimm DL, Symmans WF, Torlakovic EE, Varella L, Viale G, Weisberg TF, McShane LM, Wolff AC. Estrogen and progesterone receptor testing in breast Cancer: ASCO/CAP guideline update. J Clin Oncol. 2020;38(12):1346–66. https://doi.org/10.1200/JCO.19.02309.

  • Badve S, Kumar G (eds.). Predictive Biomarkers in Oncology. Applications in Precision Medicine. Springer International Publishing 2019.

    Google Scholar 

  • Brahmer JR, Govindan R, Anders RA, et al. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC). J Immunother Cancer. 2018;6:75. https://doi.org/10.1186/s40425-018-0382-2.

    Google Scholar 

  • College of American Pathologists. PD-L1 testing of patients with lung cancer for immunooncology therapies. CAP; 2021.

    Google Scholar 

  • Dzau VJ, Ginsburg GS, Chopra A, Goldman D, Green ED, Leonard DGB, McClellan M, Plump A, Terry SF, Yamamoto KR. Realizing the full potential of precision medicine in health and health care: a vital direction for health and health care. NAM perspectives. Discussion paper. Washington, DC: National Academy of Medicine; 2016. https://doi.org/10.31478/201609k.

    CrossRef  Google Scholar 

  • El-Deiry WS, et al. The current state of molecular testing in the treatment of patients with solid tumors, 2019. CA Cancer J Clin. 2019;69(4):305–43. https://doi.org/10.3322/caac.21560.

    CrossRef  PubMed  PubMed Central  Google Scholar 

  • Elmore JG, Longton GM, Carney PA, et al. Diagnostic concordance among pathologists interpreting breast biopsy specimens. JAMA. 2015;313(11):1122–32. https://doi.org/10.1001/jama.2015.1405.

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

  • García-Alfonso P, García-Carbonero R, García-Foncillas J, et al. Update of the recommendations for the determination of biomarkers in colorectal carcinoma: National Consensus of the Spanish Society of Medical Oncology and the Spanish Society of Pathology. Clin Transl Oncol. 2020;22:1976–91. https://doi.org/10.1007/s12094-020-02357-z.

  • Garrido P, Conde E, de Castro J, Gómez-Román JJ, Felip E, Pijuan L, Isla D, Sanz J, Paz-Ares L, López-Ríos F. Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. Clin Transl Oncol. 2020;22:989–1003.

    Google Scholar 

  • Garrison LP Jr, Babigumira JB, Masaquel A, Wang BC, Lalla D, Brammer M. The lifetime economic burden of inaccurate HER2 testing: estimating the costs of false-positive and false-negative HER2 test results in US patients with early-stage breast Cancer. Value Health. 2015;18(4):541–6. https://doi.org/10.1016/j.jval.2015.01.012.

    CrossRef  PubMed  Google Scholar 

  • Heinmoller P, Baenfer G, Grzelinksi M, Alexander K, Jasani B. Quality control of immunohistochemical and in situ hybridization predictive for treatment: Experience from international guidelines and international quality control schemes. In: Sunil Badve, George Louis Kumar (Eds.), Predictive Biomarkers in Oncology, 525–37 - December 2018. https://doi.org/10.1007/978-3-319-95228-4_48.

  • Humphries MP, Bingham V, Abdullahi Sidi F, et al. Improving the diagnostic accuracy of the PD-L1 test with image analysis and multiplex hybridization. Cancers (Basel). 2020;12(5):1114. https://doi.org/10.3390/cancers12051114.

    CAS  CrossRef  Google Scholar 

  • Lhermitte B, et al. Adequately defining tumor cell proportion in tissue samples for molecular testing improves interobserver reproducibility of its assessment. Virchows Arch. 2017;470(1):21–7.

    CrossRef  Google Scholar 

  • Matias-Guiu X, Stanta G, Carneiro F, et al. The leading role of pathology in assessing the somatic molecular alterations of cancer: position paper of the European Society of Pathology. Virchows Archiv Int J Pathol. 2020;476(4):491–7. https://doi.org/10.1007/s00428-020-02757-0.

    CrossRef  Google Scholar 

  • McKean WB, Moser JC, Rimm D, Hu-Lieskovan S. Biomarkers in precision cancer immunotherapy: promise and challenges. Am Soc Clin Oncol Educ Book. 2020;40:e275–91. https://doi.org/10.1200/EDBK_280571.

    CrossRef  PubMed  Google Scholar 

  • Miller RE, Leary A, Scott CL, Serra V, Lord CJ, Bowtell D, Chang DK, Garsed DW, Jonkers J, Ledermann JA, Nik-Zainal S. ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer. Ann Oncol. 2020;31(12):1606–22.

    Google Scholar 

  • Nass SJ, Cohen MB, Nayar R, Zutter MM, Balogh EP, Schilsky RL, Hricak H, Elenitoba-Johnson KSJ. Improving cancer diagnosis and care: patient access to high-quality oncologic pathology. Oncologist. 2019;24(10):1287–90. https://doi.org/10.1634/theoncologist.2019-0261.

    CrossRef  PubMed  PubMed Central  Google Scholar 

  • Park JJH, Siden E, Zoratti MJ, Dron L, Harari O, Singer J. Lester RT. Thorlund K, Mills EJ. Systematic review of basket trials, umbrella trials, and platform trials: A landscape analysis of master protocols. Trials 2019, 20, 572.

    Google Scholar 

  • Plebani M. The detection and prevention of errors in laboratory medicine. Ann Clin Biochem. 2010;47(Pt 2):101–10. https://doi.org/10.1258/acb.2009.009222.

    CrossRef  PubMed  Google Scholar 

  • Wasielewski RV, Hasselmann S, Rüschoff J, Fisseler-Eckhoff A, Kreipe H. Proficiency testing of immunohistochemical biomarker assays in breast cancer. Virchows Arch. 2008;453(6):537–43. https://doi.org/10.1007/s00428-008-0688-4.

    CAS  CrossRef  PubMed  Google Scholar 

  • Zhang H, Moisini I, Ajabnoor RM, Turner BM, Hicks DG. Applying the new guidelines of HER2 testing in breast cancer. Curr Oncol Rep. 2020;22(5):51. https://doi.org/10.1007/s11912-020-0901-4.

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and Permissions

Copyright information

© 2021 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Verify currency and authenticity via CrossMark

Cite this chapter

Jasani, B., Huss, R., Taylor, C.R. (2021). Role of Pathologist in Precision Cancer Diagnosis. In: Precision Cancer Medicine. Springer, Cham. https://doi.org/10.1007/978-3-030-84087-7_16

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-84087-7_16

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-84086-0

  • Online ISBN: 978-3-030-84087-7

  • eBook Packages: MedicineMedicine (R0)